Chinese General Practice ›› 2022, Vol. 25 ›› Issue (16): 1969-1977.DOI: 10.12114/j.issn.1007-9572.2022.0164
Special Issue: 社区卫生服务最新研究合集; 老年人群健康最新文章合集; 老年问题最新文章合集
• Original Research·Quality Improvement • Previous Articles Next Articles
Received:
2021-11-25
Revised:
2022-04-24
Published:
2022-06-05
Online:
2022-05-05
Contact:
Yafang HUANG
About author:
通讯作者:
黄亚芳
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0164
项目 | Beers标准 | 中国标准 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
PIP(n=266) | 非PIP(n=549) | 检验统计量值 | P值 | PIP(n=182) | 非PIP(n=633) | 检验统计量值 | P值 | |||
处方者 | ||||||||||
年龄( | 49.1±14.9 | 50.9±15.4 | 4.222a | 0.040 | 52.6±15.8 | 49.7±15.1 | 4.455a | 0.035 | ||
男性〔n(%)〕 | 93(35.0) | 212(38.6) | 1.021b | 0.312 | 79(43.4) | 226(35.7) | 3.582b | 0.058 | ||
学历〔n(%)〕 | 0.682b | 0.711 | 0.087b | 0.957 | ||||||
本科以下 | 84(31.5) | 188(34.2) | 62(34.1) | 210(33.2) | ||||||
本科 | 143(53.8) | 288(52.5) | 96(52.7) | 335(52.9) | ||||||
研究生 | 39(14.7) | 73(13.3) | 24(13.2) | 88(13.9) | ||||||
中级职称或以下〔n(%)〕 | 229(85.3) | 443(80.1) | 3.251b | 0.071 | 137(75.3) | 530(83.7) | 6.797b | 0.009 | ||
执业年限<20年〔n(%)〕 | 154(57.9) | 279(50.8) | 3.602b | 0.058 | 88(48.4) | 345(54.5) | 2.148b | 0.143 | ||
来自内科〔n(%)〕 | 250(94.0) | 508(92.5) | 0.582b | 0.446 | 166(91.2) | 592(93.5) | 1.164b | 0.281 | ||
拥有全科转岗培训证书〔n(%)〕 | 132(49.6) | 277(50.5) | 0.050b | 0.823 | 86(47.3) | 323(51.0) | 0.805b | 0.370 | ||
参加家庭医生签约〔n(%)〕 | 190(71.4) | 367(66.8) | 1.737b | 0.188 | 114(62.6) | 443(70.0) | 3.527b | 0.060 | ||
处方对象 | ||||||||||
年龄〔M(QR),岁〕 | 75.2(7.8) | 71.9(8.1) | 31.304c | <0.001 | 72.9(8.3) | 73.0(8.2) | 0.007c | 0.934 | ||
男性〔n(%)〕 | 135(50.8) | 259(47.2) | 0.917b | 0.338 | 85(46.7) | 309(48.8) | 0.253b | 0.615 | ||
疾病诊断数〔M(QR),种〕 | 3(2) | 3(2) | 2.774c | 0.096 | 3(2) | 3(2) | 2.136c | 0.144 | ||
疾病诊断〔n(%)〕 | ||||||||||
高血压 | 164(61.7) | 398(72.5) | 9.838b | 0.002 | 88(48.4) | 474(74.9) | 46.478b | <0.001 | ||
高脂血症 | 126(47.4) | 238(43.4) | 1.170b | 0.279 | 78(42.9) | 286(45.2) | 0.309b | 0.578 | ||
冠心病 | 100(37.6) | 223(40.6) | 0.686b | 0.408 | 98(53.8) | 225(35.5) | 19.789b | <0.001 | ||
糖尿病 | 90(33.8) | 190(34.6) | 0.048b | 0.827 | 40(22.0) | 240(37.9) | 15.919b | <0.001 | ||
失眠 | 50(18.8) | 14(2.6) | 65.363b | <0.001 | 47(25.8) | 17(2.7) | 104.589b | <0.001 | ||
支气管炎 | 22(8.3) | 46(8.4) | 0.003b | 0.958 | 21(11.5) | 47(7.4) | 3.128b | 0.077 | ||
骨质疏松 | 14(5.3) | 49(8.9) | 3.369b | 0.066 | 9(4.9) | 54(8.5) | 2.548b | 0.110 | ||
骨关节炎 | 14(5.3) | 39(7.1) | 0.998b | 0.318 | 18(9.9) | 35(5.5) | 4.421b | 0.036 | ||
脑血管病 | 9(3.4) | 34(6.2) | 2.830b | 0.093 | 10(5.5) | 33(5.2) | 0.022b | 0.881 | ||
处方内容 | ||||||||||
药物品种数〔M(QR),种〕 | 4(2) | 3(2) | 22.979c | <0.001 | 3(2) | 3(2) | 0.148c | 0.701 | ||
药物类别〔n(%)〕 | ||||||||||
心血管系统用药 | 173(65.0) | 440(80.1) | 21.939b | <0.001 | 107(58.8) | 506(79.9) | 33.905b | <0.001 | ||
抗血栓用药 | 166(62.4) | 143(26.0) | 100.628b | <0.001 | 106(58.2) | 203(32.1) | 41.135b | <0.001 | ||
调脂药 | 115(43.2) | 229(41.7) | 0.170b | 0.680 | 76(41.8) | 268(42.3) | 0.020b | 0.889 | ||
非胰岛素类降糖药 | 86(32.3) | 167(30.4) | 0.306b | 0.580 | 36(19.8) | 217(34.3) | 13.886b | <0.001 | ||
中枢神经系统用药 | 53(19.9) | 35(6.4) | 34.154b | <0.001 | 52(28.6) | 36(5.7) | 76.858b | <0.001 | ||
胃肠道系统用药 | 29(10.9) | 36(6.6) | 4.609b | 0.032 | 11(6.0) | 54(8.5) | 1.191b | 0.275 | ||
抗感染用药 | 22(8.3) | 38(6.9) | 0.478b | 0.489 | 19(10.4) | 41(6.5) | 3.254b | 0.071 | ||
其他泌尿生殖用药 | 20(7.5) | 37(6.7) | 0.167b | 0.683 | 10(5.5) | 47(7.4) | 0.810b | 0.368 | ||
呼吸系统用药 | 16(6.0) | 24(4.4) | 1.037b | 0.309 | 13(7.1) | 27(4.3) | 2.508b | 0.113 | ||
精神系统用药 | 12(4.5) | 16(2.9) | 1.377b | 0.241 | 7(3.8) | 21(3.3) | 0.119b | 0.730 | ||
胰岛素类降糖药 | 9(3.4) | 36(6.6) | 3.460b | 0.063 | 7(3.8) | 38(6.0) | 1.261b | 0.262 | ||
非甾体抗炎药 | 8(3.0) | 16(2.9) | 0.005b | 0.941 | 21(11.5) | 3(0.5) | 60.550b | <0.001 | ||
高尿酸血症用药 | 5(1.9) | 13 (2.4) | 0.198b | 0.657 | 6(3.3) | 12(1.9) | - | 0.257 | ||
糖皮质激素 | 3(1.1) | 8(1.5) | - | 0.999 | 2(1.1) | 9(1.4) | - | 0.999 |
Table 1 Comparison of prescriber characteristics,patient characteristics and prescription content for prescriptions with different evaluation outcomes
项目 | Beers标准 | 中国标准 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
PIP(n=266) | 非PIP(n=549) | 检验统计量值 | P值 | PIP(n=182) | 非PIP(n=633) | 检验统计量值 | P值 | |||
处方者 | ||||||||||
年龄( | 49.1±14.9 | 50.9±15.4 | 4.222a | 0.040 | 52.6±15.8 | 49.7±15.1 | 4.455a | 0.035 | ||
男性〔n(%)〕 | 93(35.0) | 212(38.6) | 1.021b | 0.312 | 79(43.4) | 226(35.7) | 3.582b | 0.058 | ||
学历〔n(%)〕 | 0.682b | 0.711 | 0.087b | 0.957 | ||||||
本科以下 | 84(31.5) | 188(34.2) | 62(34.1) | 210(33.2) | ||||||
本科 | 143(53.8) | 288(52.5) | 96(52.7) | 335(52.9) | ||||||
研究生 | 39(14.7) | 73(13.3) | 24(13.2) | 88(13.9) | ||||||
中级职称或以下〔n(%)〕 | 229(85.3) | 443(80.1) | 3.251b | 0.071 | 137(75.3) | 530(83.7) | 6.797b | 0.009 | ||
执业年限<20年〔n(%)〕 | 154(57.9) | 279(50.8) | 3.602b | 0.058 | 88(48.4) | 345(54.5) | 2.148b | 0.143 | ||
来自内科〔n(%)〕 | 250(94.0) | 508(92.5) | 0.582b | 0.446 | 166(91.2) | 592(93.5) | 1.164b | 0.281 | ||
拥有全科转岗培训证书〔n(%)〕 | 132(49.6) | 277(50.5) | 0.050b | 0.823 | 86(47.3) | 323(51.0) | 0.805b | 0.370 | ||
参加家庭医生签约〔n(%)〕 | 190(71.4) | 367(66.8) | 1.737b | 0.188 | 114(62.6) | 443(70.0) | 3.527b | 0.060 | ||
处方对象 | ||||||||||
年龄〔M(QR),岁〕 | 75.2(7.8) | 71.9(8.1) | 31.304c | <0.001 | 72.9(8.3) | 73.0(8.2) | 0.007c | 0.934 | ||
男性〔n(%)〕 | 135(50.8) | 259(47.2) | 0.917b | 0.338 | 85(46.7) | 309(48.8) | 0.253b | 0.615 | ||
疾病诊断数〔M(QR),种〕 | 3(2) | 3(2) | 2.774c | 0.096 | 3(2) | 3(2) | 2.136c | 0.144 | ||
疾病诊断〔n(%)〕 | ||||||||||
高血压 | 164(61.7) | 398(72.5) | 9.838b | 0.002 | 88(48.4) | 474(74.9) | 46.478b | <0.001 | ||
高脂血症 | 126(47.4) | 238(43.4) | 1.170b | 0.279 | 78(42.9) | 286(45.2) | 0.309b | 0.578 | ||
冠心病 | 100(37.6) | 223(40.6) | 0.686b | 0.408 | 98(53.8) | 225(35.5) | 19.789b | <0.001 | ||
糖尿病 | 90(33.8) | 190(34.6) | 0.048b | 0.827 | 40(22.0) | 240(37.9) | 15.919b | <0.001 | ||
失眠 | 50(18.8) | 14(2.6) | 65.363b | <0.001 | 47(25.8) | 17(2.7) | 104.589b | <0.001 | ||
支气管炎 | 22(8.3) | 46(8.4) | 0.003b | 0.958 | 21(11.5) | 47(7.4) | 3.128b | 0.077 | ||
骨质疏松 | 14(5.3) | 49(8.9) | 3.369b | 0.066 | 9(4.9) | 54(8.5) | 2.548b | 0.110 | ||
骨关节炎 | 14(5.3) | 39(7.1) | 0.998b | 0.318 | 18(9.9) | 35(5.5) | 4.421b | 0.036 | ||
脑血管病 | 9(3.4) | 34(6.2) | 2.830b | 0.093 | 10(5.5) | 33(5.2) | 0.022b | 0.881 | ||
处方内容 | ||||||||||
药物品种数〔M(QR),种〕 | 4(2) | 3(2) | 22.979c | <0.001 | 3(2) | 3(2) | 0.148c | 0.701 | ||
药物类别〔n(%)〕 | ||||||||||
心血管系统用药 | 173(65.0) | 440(80.1) | 21.939b | <0.001 | 107(58.8) | 506(79.9) | 33.905b | <0.001 | ||
抗血栓用药 | 166(62.4) | 143(26.0) | 100.628b | <0.001 | 106(58.2) | 203(32.1) | 41.135b | <0.001 | ||
调脂药 | 115(43.2) | 229(41.7) | 0.170b | 0.680 | 76(41.8) | 268(42.3) | 0.020b | 0.889 | ||
非胰岛素类降糖药 | 86(32.3) | 167(30.4) | 0.306b | 0.580 | 36(19.8) | 217(34.3) | 13.886b | <0.001 | ||
中枢神经系统用药 | 53(19.9) | 35(6.4) | 34.154b | <0.001 | 52(28.6) | 36(5.7) | 76.858b | <0.001 | ||
胃肠道系统用药 | 29(10.9) | 36(6.6) | 4.609b | 0.032 | 11(6.0) | 54(8.5) | 1.191b | 0.275 | ||
抗感染用药 | 22(8.3) | 38(6.9) | 0.478b | 0.489 | 19(10.4) | 41(6.5) | 3.254b | 0.071 | ||
其他泌尿生殖用药 | 20(7.5) | 37(6.7) | 0.167b | 0.683 | 10(5.5) | 47(7.4) | 0.810b | 0.368 | ||
呼吸系统用药 | 16(6.0) | 24(4.4) | 1.037b | 0.309 | 13(7.1) | 27(4.3) | 2.508b | 0.113 | ||
精神系统用药 | 12(4.5) | 16(2.9) | 1.377b | 0.241 | 7(3.8) | 21(3.3) | 0.119b | 0.730 | ||
胰岛素类降糖药 | 9(3.4) | 36(6.6) | 3.460b | 0.063 | 7(3.8) | 38(6.0) | 1.261b | 0.262 | ||
非甾体抗炎药 | 8(3.0) | 16(2.9) | 0.005b | 0.941 | 21(11.5) | 3(0.5) | 60.550b | <0.001 | ||
高尿酸血症用药 | 5(1.9) | 13 (2.4) | 0.198b | 0.657 | 6(3.3) | 12(1.9) | - | 0.257 | ||
糖皮质激素 | 3(1.1) | 8(1.5) | - | 0.999 | 2(1.1) | 9(1.4) | - | 0.999 |
自变量 | Beers标准 | 中国标准 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
b | OR(95%CI) | SE | Wald χ2值 | P值 | b | OR(95%CI) | SE | Wald χ2值 | P值 | ||||
处方者 | |||||||||||||
年龄(以实际值纳入) | 0.012 | 1.012(0.951,1.078) | 0.032 | 0.142 | 0.707 | 0.059 | 1.061(0.992,1.135) | 0.034 | 2.959 | 0.085 | |||
职称(以高级或副高级为参照) | |||||||||||||
中级或以下 | 0.425 | 1.529(0.759,3.081) | 0.357 | 1.412 | 0.235 | -0.319 | 0.727(0.343,1.539) | 0.382 | 0.695 | 0.405 | |||
执业年限(年,以≥20为参照) | |||||||||||||
<20 | -0.105 | 0.901(0.467,1.736) | 0.335 | 0.098 | 0.755 | -0.227 | 0.797(0.387,1.641) | 0.368 | 0.378 | 0.539 | |||
参加家庭医生签约(以否为参照) | |||||||||||||
是 | 0.130 | 1.138(0.216,5.987) | 0.847 | 0.023 | 0.878 | 1.446 | 4.245(0.765,23.550) | 0.874 | 2.736 | 0.098 | |||
处方对象 | |||||||||||||
年龄(以实际值纳入) | 0.084 | 1.087(1.062,1.114) | 0.012 | 47.001 | <0.001 | -0.009 | 0.992(0.967,1.017) | 0.013 | 0.441 | 0.507 | |||
疾病诊断数(以实际值纳入) | 0.154 | 1.166(0.931,1.462) | 0.115 | 1.786 | 0.181 | 0.207 | 1.230(0.966,1.565) | 0.123 | 2.821 | 0.093 | |||
疾病诊断 | |||||||||||||
高血压(以无为参照) | |||||||||||||
有 | -0.376 | 0.687(0.388,1.216) | 0.292 | 1.660 | 0.198 | -0.954 | 0.385(0.218,0.680) | 0.291 | 10.803 | 0.001 | |||
高脂血症(以无为参照) | |||||||||||||
有 | -0.339 | 0.712(0.464,1.094) | 0.219 | 2.398 | 0.122 | -0.608 | 0.545(0.336,0.882) | 0.246 | 6.107 | 0.014 | |||
冠心病(以无为参照) | |||||||||||||
有 | -1.046 | 0.351(0.218,0.566) | 0.243 | 18.546 | <0.001 | 0.722 | 2.059(1.261,3.362) | 0.250 | 8.341 | 0.004 | |||
糖尿病(以无为参照) | |||||||||||||
有 | -0.532 | 0.587(0.204,1.690) | 0.539 | 0.974 | 0.324 | -1.033 | 0.356(0.108,1.170) | 0.607 | 2.893 | 0.089 | |||
失眠(以无为参照) | |||||||||||||
有 | 2.936 | 18.835(6.876,51.597) | 0.514 | 32.602 | <0.001 | 2.169 | 8.750(3.561,21.503) | 0.459 | 22.359 | <0.001 | |||
支气管炎(以无为参照) | |||||||||||||
有 | -0.262 | 0.770(0.365,1.624) | 0.381 | 0.472 | 0.492 | 0.157 | 1.170(0.529,2.587) | 0.405 | 0.150 | 0.699 | |||
脑血管病(以无为参照) | |||||||||||||
有 | -0.403 | 0.668(0.276,1.618) | 0.452 | 0.797 | 0.372 | -0.138 | 0.871(0.344,2.206) | 0.474 | 0.085 | 0.771 | |||
处方内容 | |||||||||||||
药物品种数(以实际值纳入) | 0.220 | 1.247(1.029,1.511) | 0.098 | 5.076 | 0.024 | 0.020 | 1.020(0.828,1.257) | 0.106 | 0.036 | 0.850 | |||
药物类别 | |||||||||||||
心血管系统用药(以无为参照) | |||||||||||||
有 | -0.952 | 0.386(0.208,0.717) | 0.316 | 9.060 | 0.003 | -0.568 | 0.567(0.304,1.057) | 0.318 | 3.187 | 0.074 | |||
抗血栓用药(以无为参照) | |||||||||||||
有 | 2.468 | 11.798(7.353,18.929) | 0.241 | 104.681 | <0.001 | 1.731 | 5.647(3.426,9.307) | 0.255 | 46.093 | <0.001 | |||
中枢神经系统用药(以无为参照) | |||||||||||||
有 | 0.180 | 0.835(0.349,2.000) | 0.446 | 0.164 | 0.686 | 0.893 | 2.443(1.084,5.507) | 0.415 | 4.641 | 0.031 | |||
胃肠道系统用药(以无为参照) | |||||||||||||
有 | 0.945 | 2.572(1.316,5.025) | 0.342 | 7.640 | 0.005 | -0.768 | 0.464(0.198,1.087) | 0.434 | 3.128 | 0.077 | |||
非胰岛素类降糖药(以无为参照) | |||||||||||||
有 | 0.712 | 2.039(0.715,5.817) | 0.535 | 1.773 | 0.183 | -0.085 | 0.918(0.286,2.945) | 0.595 | 0.021 | 0.886 | |||
胰岛素类降糖药(以无为参照) | |||||||||||||
有 | -1.351 | 0.259(0.095,0.707) | 0.513 | 6.943 | 0.008 | 0.056 | 1.058(0.329,3.399) | 0.596 | 0.009 | 0.925 | |||
非甾体抗炎药(以无为参照) | |||||||||||||
有 | 0.051 | 1.053(0.485,2.283) | 0.395 | 0.017 | 0.897 | 0.612 | 1.845(0.803,4.237) | 0.424 | 2.083 | 0.149 |
Table 2 Results of binary Logistic regression analysis of factors influencing PIP prescribing in older community-dwelling patients
自变量 | Beers标准 | 中国标准 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
b | OR(95%CI) | SE | Wald χ2值 | P值 | b | OR(95%CI) | SE | Wald χ2值 | P值 | ||||
处方者 | |||||||||||||
年龄(以实际值纳入) | 0.012 | 1.012(0.951,1.078) | 0.032 | 0.142 | 0.707 | 0.059 | 1.061(0.992,1.135) | 0.034 | 2.959 | 0.085 | |||
职称(以高级或副高级为参照) | |||||||||||||
中级或以下 | 0.425 | 1.529(0.759,3.081) | 0.357 | 1.412 | 0.235 | -0.319 | 0.727(0.343,1.539) | 0.382 | 0.695 | 0.405 | |||
执业年限(年,以≥20为参照) | |||||||||||||
<20 | -0.105 | 0.901(0.467,1.736) | 0.335 | 0.098 | 0.755 | -0.227 | 0.797(0.387,1.641) | 0.368 | 0.378 | 0.539 | |||
参加家庭医生签约(以否为参照) | |||||||||||||
是 | 0.130 | 1.138(0.216,5.987) | 0.847 | 0.023 | 0.878 | 1.446 | 4.245(0.765,23.550) | 0.874 | 2.736 | 0.098 | |||
处方对象 | |||||||||||||
年龄(以实际值纳入) | 0.084 | 1.087(1.062,1.114) | 0.012 | 47.001 | <0.001 | -0.009 | 0.992(0.967,1.017) | 0.013 | 0.441 | 0.507 | |||
疾病诊断数(以实际值纳入) | 0.154 | 1.166(0.931,1.462) | 0.115 | 1.786 | 0.181 | 0.207 | 1.230(0.966,1.565) | 0.123 | 2.821 | 0.093 | |||
疾病诊断 | |||||||||||||
高血压(以无为参照) | |||||||||||||
有 | -0.376 | 0.687(0.388,1.216) | 0.292 | 1.660 | 0.198 | -0.954 | 0.385(0.218,0.680) | 0.291 | 10.803 | 0.001 | |||
高脂血症(以无为参照) | |||||||||||||
有 | -0.339 | 0.712(0.464,1.094) | 0.219 | 2.398 | 0.122 | -0.608 | 0.545(0.336,0.882) | 0.246 | 6.107 | 0.014 | |||
冠心病(以无为参照) | |||||||||||||
有 | -1.046 | 0.351(0.218,0.566) | 0.243 | 18.546 | <0.001 | 0.722 | 2.059(1.261,3.362) | 0.250 | 8.341 | 0.004 | |||
糖尿病(以无为参照) | |||||||||||||
有 | -0.532 | 0.587(0.204,1.690) | 0.539 | 0.974 | 0.324 | -1.033 | 0.356(0.108,1.170) | 0.607 | 2.893 | 0.089 | |||
失眠(以无为参照) | |||||||||||||
有 | 2.936 | 18.835(6.876,51.597) | 0.514 | 32.602 | <0.001 | 2.169 | 8.750(3.561,21.503) | 0.459 | 22.359 | <0.001 | |||
支气管炎(以无为参照) | |||||||||||||
有 | -0.262 | 0.770(0.365,1.624) | 0.381 | 0.472 | 0.492 | 0.157 | 1.170(0.529,2.587) | 0.405 | 0.150 | 0.699 | |||
脑血管病(以无为参照) | |||||||||||||
有 | -0.403 | 0.668(0.276,1.618) | 0.452 | 0.797 | 0.372 | -0.138 | 0.871(0.344,2.206) | 0.474 | 0.085 | 0.771 | |||
处方内容 | |||||||||||||
药物品种数(以实际值纳入) | 0.220 | 1.247(1.029,1.511) | 0.098 | 5.076 | 0.024 | 0.020 | 1.020(0.828,1.257) | 0.106 | 0.036 | 0.850 | |||
药物类别 | |||||||||||||
心血管系统用药(以无为参照) | |||||||||||||
有 | -0.952 | 0.386(0.208,0.717) | 0.316 | 9.060 | 0.003 | -0.568 | 0.567(0.304,1.057) | 0.318 | 3.187 | 0.074 | |||
抗血栓用药(以无为参照) | |||||||||||||
有 | 2.468 | 11.798(7.353,18.929) | 0.241 | 104.681 | <0.001 | 1.731 | 5.647(3.426,9.307) | 0.255 | 46.093 | <0.001 | |||
中枢神经系统用药(以无为参照) | |||||||||||||
有 | 0.180 | 0.835(0.349,2.000) | 0.446 | 0.164 | 0.686 | 0.893 | 2.443(1.084,5.507) | 0.415 | 4.641 | 0.031 | |||
胃肠道系统用药(以无为参照) | |||||||||||||
有 | 0.945 | 2.572(1.316,5.025) | 0.342 | 7.640 | 0.005 | -0.768 | 0.464(0.198,1.087) | 0.434 | 3.128 | 0.077 | |||
非胰岛素类降糖药(以无为参照) | |||||||||||||
有 | 0.712 | 2.039(0.715,5.817) | 0.535 | 1.773 | 0.183 | -0.085 | 0.918(0.286,2.945) | 0.595 | 0.021 | 0.886 | |||
胰岛素类降糖药(以无为参照) | |||||||||||||
有 | -1.351 | 0.259(0.095,0.707) | 0.513 | 6.943 | 0.008 | 0.056 | 1.058(0.329,3.399) | 0.596 | 0.009 | 0.925 | |||
非甾体抗炎药(以无为参照) | |||||||||||||
有 | 0.051 | 1.053(0.485,2.283) | 0.395 | 0.017 | 0.897 | 0.612 | 1.845(0.803,4.237) | 0.424 | 2.083 | 0.149 |
自变量 | Beers标准 | 中国标准 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
b | OR(95%CI) | SE | Wald χ2值 | P值 | b | OR(95%CI) | SE | Wald χ2值 | P值 | ||||
处方者 | |||||||||||||
年龄(以实际值纳入) | -0.024 | 0.976(0.906,1.051) | 0.038 | 0.420 | 0.517 | 0.056 | 1.057(0.973,1.149) | 0.042 | 1.713 | 0.191 | |||
职称(以高级或副高级为参照) | |||||||||||||
中级或以下 | 0.488 | 1.629(0.738,3.596) | 0.404 | 1.459 | 0.227 | -0.003 | 0.997(0.418,2.380) | 0.444 | 0.001 | 0.995 | |||
执业年限(年,以≥20为参照) | |||||||||||||
<20 | -0.073 | 0.929(0.437,1.973) | 0.384 | 0.037 | 0.847 | -0.235 | 0.791(0.344,1.819) | 0.425 | 0.306 | 0.580 | |||
参加家庭医生签约(以否为参照) | |||||||||||||
是 | -1.183 | 0.306(0.043,2.195) | 1.005 | 1.387 | 0.239 | 1.038 | 2.824(0.328,24.287) | 1.098 | 0.894 | 0.344 | |||
处方对象 | |||||||||||||
年龄(以实际值纳入) | 0.098 | 1.103(1.068,1.138) | 0.016 | 36.029 | <0.001 | 0.017 | 1.017(0.983,1.052) | 0.017 | 0.969 | 0.325 | |||
疾病诊断数(以实际值纳入) | 0.181 | 1.199(0.930,1.544) | 0.129 | 1.965 | 0.079 | 0.181 | 1.082(0.822,1.425) | 0.140 | 0.319 | 0.572 | |||
临床诊断 | |||||||||||||
高血压(以无为参照) | |||||||||||||
有 | 0.098 | 1.103(1.068,1.138) | 0.016 | 36.029 | <0.001 | -0.944 | 0.389(0.210,0.723) | 0.316 | 8.930 | 0.002 | |||
高脂血症(以无为参照) | |||||||||||||
有 | -0.369 | 0.691(0.424,1.127) | 0.249 | 2.197 | 0.138 | -0.401 | 0.670(0.388-1.156) | 0.279 | 2.071 | 0.150 | |||
冠心病(以无为参照) | |||||||||||||
有 | -1.036 | 0.355(0.208,0.605) | 0.272 | 14.503 | <0.001 | 0.790 | 2.203(1.253,3.873) | 0.288 | 7.518 | 0.006 | |||
糖尿病(以无为参照) | |||||||||||||
有 | -0.654 | 0.520(0.160,1.687) | 0.601 | 1.186 | 0.276 | -1.048 | 0.351(0.092,1.333) | 0.681 | 2.366 | 0.124 | |||
失眠(以无为参照) | |||||||||||||
有 | 2.803 | 16.494(5.178,52.543) | 0.591 | 22.484 | <0.001 | 1.742 | 5.709(2.042,15.965) | 0.525 | 11.027 | 0.001 | |||
支气管炎(以无为参照) | |||||||||||||
有 | -0.171 | 0.843(0.380,1.871) | 0.407 | 0.177 | 0.674 | 0.412 | 1.510(0.657,3.467) | 0.424 | 0.942 | 0.332 | |||
脑血管病(以无为参照) | |||||||||||||
有 | -0.157 | 0.855(0.334,2.184) | 0.479 | 0.108 | 0.743 | -0.484 | 0.616(0.200,1.901) | 0.575 | 0.709 | 0.400 | |||
处方内容 | |||||||||||||
药物品种数(以实际值纳入) | 0.190 | 1.209(0.979,1.494) | 0.107 | 3.116 | 0.078 | -0.017 | 0.983(0.774,1.250) | 0.122 | 0.019 | 0.892 | |||
药物类别 | |||||||||||||
心血管系统用药(以无为参照) | |||||||||||||
有 | -1.006 | 0.366(0.184,0.728) | 0.352 | 8.192 | 0.004 | -0.475 | 0.622(0.310,1.250) | 0.356 | 1.778 | 0.182 | |||
抗血栓用药(以无为参照) | |||||||||||||
有 | 2.827 | 16.888(9.858,28.928) | 0.275 | 105.938 | <0.001 | 1.697 | 5.459(3.125,9.536) | 0.285 | 35.559 | <0.001 | |||
中枢神经系统用药(以无为参照) | |||||||||||||
有 | -0.423 | 0.655(0.246,1.745) | 0.500 | 0.717 | 0.397 | 1.028 | 2.795(1.102,7.087) | 0.475 | 4.687 | 0.030 | |||
胃肠道系统用药(以无为参照) | |||||||||||||
有 | 0.649 | 1.914(0.897,4.085) | 0.387 | 2.818 | 0.093 | -0.847 | 0.429(0.165,1.113) | 0.487 | 3.030 | 0.082 | |||
非胰岛素类降糖药(以无为参照) | |||||||||||||
有 | 0.696 | 2.006(0.629,6.401) | 0.592 | 1.384 | 0.240 | -0.112 | 0.894(0.246,3.249) | 0.658 | 0.029 | 0.865 | |||
胰岛素类降糖药(以无为参照) | |||||||||||||
有 | -1.245 | 0.288(0.095,0.876) | 0.568 | 4.812 | 0.028 | 0.540 | 1.717(0.493,5.975) | 0.636 | 0.721 | 0.396 | |||
非甾体抗炎药(以无为参照) | |||||||||||||
有 | 0.155 | 1.168(0.498,2.740) | 0.435 | 0.127 | 0.721 | 0.647 | 1.910(0.749,4.874) | 0.478 | 1.833 | 0.175 |
Table 3 Results of sensitivity analysis of binary Logistic regression of factors influencing the prescription of PIP for elderly patients in community outpatient clinics
自变量 | Beers标准 | 中国标准 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
b | OR(95%CI) | SE | Wald χ2值 | P值 | b | OR(95%CI) | SE | Wald χ2值 | P值 | ||||
处方者 | |||||||||||||
年龄(以实际值纳入) | -0.024 | 0.976(0.906,1.051) | 0.038 | 0.420 | 0.517 | 0.056 | 1.057(0.973,1.149) | 0.042 | 1.713 | 0.191 | |||
职称(以高级或副高级为参照) | |||||||||||||
中级或以下 | 0.488 | 1.629(0.738,3.596) | 0.404 | 1.459 | 0.227 | -0.003 | 0.997(0.418,2.380) | 0.444 | 0.001 | 0.995 | |||
执业年限(年,以≥20为参照) | |||||||||||||
<20 | -0.073 | 0.929(0.437,1.973) | 0.384 | 0.037 | 0.847 | -0.235 | 0.791(0.344,1.819) | 0.425 | 0.306 | 0.580 | |||
参加家庭医生签约(以否为参照) | |||||||||||||
是 | -1.183 | 0.306(0.043,2.195) | 1.005 | 1.387 | 0.239 | 1.038 | 2.824(0.328,24.287) | 1.098 | 0.894 | 0.344 | |||
处方对象 | |||||||||||||
年龄(以实际值纳入) | 0.098 | 1.103(1.068,1.138) | 0.016 | 36.029 | <0.001 | 0.017 | 1.017(0.983,1.052) | 0.017 | 0.969 | 0.325 | |||
疾病诊断数(以实际值纳入) | 0.181 | 1.199(0.930,1.544) | 0.129 | 1.965 | 0.079 | 0.181 | 1.082(0.822,1.425) | 0.140 | 0.319 | 0.572 | |||
临床诊断 | |||||||||||||
高血压(以无为参照) | |||||||||||||
有 | 0.098 | 1.103(1.068,1.138) | 0.016 | 36.029 | <0.001 | -0.944 | 0.389(0.210,0.723) | 0.316 | 8.930 | 0.002 | |||
高脂血症(以无为参照) | |||||||||||||
有 | -0.369 | 0.691(0.424,1.127) | 0.249 | 2.197 | 0.138 | -0.401 | 0.670(0.388-1.156) | 0.279 | 2.071 | 0.150 | |||
冠心病(以无为参照) | |||||||||||||
有 | -1.036 | 0.355(0.208,0.605) | 0.272 | 14.503 | <0.001 | 0.790 | 2.203(1.253,3.873) | 0.288 | 7.518 | 0.006 | |||
糖尿病(以无为参照) | |||||||||||||
有 | -0.654 | 0.520(0.160,1.687) | 0.601 | 1.186 | 0.276 | -1.048 | 0.351(0.092,1.333) | 0.681 | 2.366 | 0.124 | |||
失眠(以无为参照) | |||||||||||||
有 | 2.803 | 16.494(5.178,52.543) | 0.591 | 22.484 | <0.001 | 1.742 | 5.709(2.042,15.965) | 0.525 | 11.027 | 0.001 | |||
支气管炎(以无为参照) | |||||||||||||
有 | -0.171 | 0.843(0.380,1.871) | 0.407 | 0.177 | 0.674 | 0.412 | 1.510(0.657,3.467) | 0.424 | 0.942 | 0.332 | |||
脑血管病(以无为参照) | |||||||||||||
有 | -0.157 | 0.855(0.334,2.184) | 0.479 | 0.108 | 0.743 | -0.484 | 0.616(0.200,1.901) | 0.575 | 0.709 | 0.400 | |||
处方内容 | |||||||||||||
药物品种数(以实际值纳入) | 0.190 | 1.209(0.979,1.494) | 0.107 | 3.116 | 0.078 | -0.017 | 0.983(0.774,1.250) | 0.122 | 0.019 | 0.892 | |||
药物类别 | |||||||||||||
心血管系统用药(以无为参照) | |||||||||||||
有 | -1.006 | 0.366(0.184,0.728) | 0.352 | 8.192 | 0.004 | -0.475 | 0.622(0.310,1.250) | 0.356 | 1.778 | 0.182 | |||
抗血栓用药(以无为参照) | |||||||||||||
有 | 2.827 | 16.888(9.858,28.928) | 0.275 | 105.938 | <0.001 | 1.697 | 5.459(3.125,9.536) | 0.285 | 35.559 | <0.001 | |||
中枢神经系统用药(以无为参照) | |||||||||||||
有 | -0.423 | 0.655(0.246,1.745) | 0.500 | 0.717 | 0.397 | 1.028 | 2.795(1.102,7.087) | 0.475 | 4.687 | 0.030 | |||
胃肠道系统用药(以无为参照) | |||||||||||||
有 | 0.649 | 1.914(0.897,4.085) | 0.387 | 2.818 | 0.093 | -0.847 | 0.429(0.165,1.113) | 0.487 | 3.030 | 0.082 | |||
非胰岛素类降糖药(以无为参照) | |||||||||||||
有 | 0.696 | 2.006(0.629,6.401) | 0.592 | 1.384 | 0.240 | -0.112 | 0.894(0.246,3.249) | 0.658 | 0.029 | 0.865 | |||
胰岛素类降糖药(以无为参照) | |||||||||||||
有 | -1.245 | 0.288(0.095,0.876) | 0.568 | 4.812 | 0.028 | 0.540 | 1.717(0.493,5.975) | 0.636 | 0.721 | 0.396 | |||
非甾体抗炎药(以无为参照) | |||||||||||||
有 | 0.155 | 1.168(0.498,2.740) | 0.435 | 0.127 | 0.721 | 0.647 | 1.910(0.749,4.874) | 0.478 | 1.833 | 0.175 |
Beers标准下不适当用药涉及药物类别及具体药物 | 例次(n=302) | 中国标准下不适当用药涉及的药物类别及具体药物 | 例次(n=205) | ||||
---|---|---|---|---|---|---|---|
老年人潜在不适当用药 | 中国老年人潜在不适当用药A级预警 | ||||||
中枢神经系统用药 | 抗血栓药 | ||||||
艾司唑仑 | 35(11.6) | 氯吡格雷 | 92(44.9) | ||||
唑吡坦 | 11(3.6) | 中枢神经系统用药 | |||||
劳拉西泮 | 2(0.7) | 艾司唑仑 | 35(17.1) | ||||
地西泮 | 1(0.3) | 唑吡坦 | 11(5.4) | ||||
内分泌系统糖尿病用药(非胰岛素) | 尼麦角林 | ||||||
格列苯脲 | 42(13.9) | 劳拉西泮 | 2(1.0) | ||||
胃肠道系统用药 | 口服非甾体抗炎药 | ||||||
雷贝拉唑 | 10(3.3) | 布洛芬 | 10(4.9) | ||||
奥美拉唑 | 10(3.3) | 双氯芬酸 | 10(4.9) | ||||
心血管系统用药 | 呼吸系统用药 | ||||||
特拉唑嗪 | 4(1.3) | 复方盐酸伪麻黄碱(含氯苯那敏) | 9(4.4) | ||||
复方利血平 | 4(1.3) | 茶碱 | 3(1.5) | ||||
地高辛 | 3(1.0) | 复方银翘氨敏胶囊(含氯苯那敏) | 1(0.5) | ||||
呼吸系统用药a | 心血管系统用药 | ||||||
复方盐酸伪麻黄碱(含氯苯那敏) | 6(2.0) | 复方利血平 | 4(2.0) | ||||
氨酚伪麻美芬/氨麻美敏片(含氯苯那敏) | 5(1.7) | 地高辛 | 3(1.5) | ||||
复方银翘氨敏胶囊(含氯苯那敏) | 1(0.3) | 其他泌尿生殖系统用药(不包括抗感染) | |||||
口服非甾体抗炎药 | 螺内酯 | 3(1.5) | |||||
双氯芬酸 | 3(1.0) | 中国老年人疾病状态下潜在不适当用药A级预警 | |||||
布洛芬 | 4(1.3) | 口服非体甾类抗炎药用药 | |||||
抗胆碱能药物(抗过敏等) | 布洛芬 | 5(2.4) | |||||
颠茄生物碱 | 4(1.3) | 双氯芬酸 | 4(2.0) | ||||
茶苯海明 | 1(0.3) | 中国老年人潜在不适当用药B级预警 | |||||
帕罗西汀 | 1(0.3) | 抗胆碱能药物 | |||||
老年人慎用药物 | 颠茄生物碱 | 4(2.0) | |||||
抗血栓药 | 中枢神经系统用药 | ||||||
阿司匹林 | 134(44.4) | 地西泮 | 1(0.5) | ||||
达比加群 | 6(2.0) | 中国老年人疾病状态下潜在不适当用药B级预警 | |||||
其他泌尿生殖系统用药(不包括抗感染) | 心血管系统用药 | ||||||
托拉塞米 | 3(1.0) | 复方利血平 | 4(2.0) | ||||
螺内酯 | 2(0.7) | ||||||
呋塞米 | 1(0.3) | ||||||
呼吸系统用药a | |||||||
氨酚伪麻美芬/氨麻美敏片(含右美沙芬) | 5(1.7) | ||||||
精神系统用药 | |||||||
卡马西平 | 4(1.3) |
Table 4 Distribution of inappropriately medications in PIP of elderly patients in community outpatient clinics according to Beers,China criteria
Beers标准下不适当用药涉及药物类别及具体药物 | 例次(n=302) | 中国标准下不适当用药涉及的药物类别及具体药物 | 例次(n=205) | ||||
---|---|---|---|---|---|---|---|
老年人潜在不适当用药 | 中国老年人潜在不适当用药A级预警 | ||||||
中枢神经系统用药 | 抗血栓药 | ||||||
艾司唑仑 | 35(11.6) | 氯吡格雷 | 92(44.9) | ||||
唑吡坦 | 11(3.6) | 中枢神经系统用药 | |||||
劳拉西泮 | 2(0.7) | 艾司唑仑 | 35(17.1) | ||||
地西泮 | 1(0.3) | 唑吡坦 | 11(5.4) | ||||
内分泌系统糖尿病用药(非胰岛素) | 尼麦角林 | ||||||
格列苯脲 | 42(13.9) | 劳拉西泮 | 2(1.0) | ||||
胃肠道系统用药 | 口服非甾体抗炎药 | ||||||
雷贝拉唑 | 10(3.3) | 布洛芬 | 10(4.9) | ||||
奥美拉唑 | 10(3.3) | 双氯芬酸 | 10(4.9) | ||||
心血管系统用药 | 呼吸系统用药 | ||||||
特拉唑嗪 | 4(1.3) | 复方盐酸伪麻黄碱(含氯苯那敏) | 9(4.4) | ||||
复方利血平 | 4(1.3) | 茶碱 | 3(1.5) | ||||
地高辛 | 3(1.0) | 复方银翘氨敏胶囊(含氯苯那敏) | 1(0.5) | ||||
呼吸系统用药a | 心血管系统用药 | ||||||
复方盐酸伪麻黄碱(含氯苯那敏) | 6(2.0) | 复方利血平 | 4(2.0) | ||||
氨酚伪麻美芬/氨麻美敏片(含氯苯那敏) | 5(1.7) | 地高辛 | 3(1.5) | ||||
复方银翘氨敏胶囊(含氯苯那敏) | 1(0.3) | 其他泌尿生殖系统用药(不包括抗感染) | |||||
口服非甾体抗炎药 | 螺内酯 | 3(1.5) | |||||
双氯芬酸 | 3(1.0) | 中国老年人疾病状态下潜在不适当用药A级预警 | |||||
布洛芬 | 4(1.3) | 口服非体甾类抗炎药用药 | |||||
抗胆碱能药物(抗过敏等) | 布洛芬 | 5(2.4) | |||||
颠茄生物碱 | 4(1.3) | 双氯芬酸 | 4(2.0) | ||||
茶苯海明 | 1(0.3) | 中国老年人潜在不适当用药B级预警 | |||||
帕罗西汀 | 1(0.3) | 抗胆碱能药物 | |||||
老年人慎用药物 | 颠茄生物碱 | 4(2.0) | |||||
抗血栓药 | 中枢神经系统用药 | ||||||
阿司匹林 | 134(44.4) | 地西泮 | 1(0.5) | ||||
达比加群 | 6(2.0) | 中国老年人疾病状态下潜在不适当用药B级预警 | |||||
其他泌尿生殖系统用药(不包括抗感染) | 心血管系统用药 | ||||||
托拉塞米 | 3(1.0) | 复方利血平 | 4(2.0) | ||||
螺内酯 | 2(0.7) | ||||||
呋塞米 | 1(0.3) | ||||||
呼吸系统用药a | |||||||
氨酚伪麻美芬/氨麻美敏片(含右美沙芬) | 5(1.7) | ||||||
精神系统用药 | |||||||
卡马西平 | 4(1.3) |
[1] |
|
[2] |
|
[3] |
迟俊婷,牛晓丹,阮海慧,等. 潜在不适当用药对老年人不良健康结局影响的系统评价[J]. 中华护理教育,2020,17(3):268-274. DOI:10.3761/j.issn.1672-9234.2020.03.017.
|
[4] |
|
[5] |
章陈怡,潘志刚,陈实,等. 上海社区老年慢性病患者潜在不适当用药情况及影响因素 [J]. 中华全科医师杂志,2020,19 (4):324-328.
|
[6] |
吴玉婷,李智勤. 老年病科门诊患者潜在不适当用药调查及风险因素分析[J]. 药学服务与研究,2020,20(2):122-131.
|
[7] |
陈彦文,叶勇峰,王阿妮,等. 门诊老年患者潜在不适当用药调查及影响因素分析[J]. 中国药业,2020,29(4):27-30.
|
[8] |
张莹,田方圆,李海霞,等. 成都市老年门诊患者潜在不适当用药评估及风险因素分析[J]. 中国药师,2021,24(6):1117-1122. DOI:10.3969/j.issn.1008-049X.2021.06.026.
|
[9] |
李雪冰,王鹏. 斋堂社区老年人潜在不适当用药及其相关因素[J]. 中华老年多器官疾病杂志,2020,19(5):340-344. DOI:10.11915/j.issn.1671-5403.2020.05.080.
|
[10] |
舒冰,方玉婷,李民,等. 老年多重用药患者潜在不适当用药情况及其影响因素研究[J]. 中国全科医学,2021,24(17):2134-2147. DOI:10.12114/j.issn.1007-9572.2021.00.489.
|
[11] |
邱珊娇,唐干益,黄文静,等. Beers标准(2019)和中国老年人潜在不适当用药判断标准(2017版)评估社区老年共病患者的不适当用药分析[J]. 中国全科医学,2020,23(s1):34-38.
|
[12] |
The American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults[J]. J Am Geriatr Soc,2019,67(4):674-694. DOI:10.1111/jgs.15767.
|
[13] |
肖坚,黄娅敏,刘可可,等. 美国老年医学会2019版潜在不适当用药的Beers标准解读[J]. 药物流行病学杂志,2019,28(5):341-350.
|
[14] |
中国老年保健医学研究会合理用药分会,中华医学会老年医学分会,中国药学会老年药学专业委员会,等. 中国老年人潜在不适当用药判断标准(2017版)[J]. 药物不良反应杂志,2018,20(1):1-8.
|
[15] |
梁华玉,张兰,邢晓璇,等. 中国六城市门急诊老年患者潜在不适当用药情况及影响因素分析[J]. 药物不良反应杂志,2017,19(1):22-30.
|
[16] |
|
[17] |
舒冰,刘玉龙,张圣雨,等. 老年人潜在不适当用药评价工具2019年版Beers标准解读[J]. 中国全科医学,2019,22(33):4041-4046. DOI:10.12114/j.issn.1007-9572.2019.00.435.
|
[18] |
|
[19] |
|
[20] |
赵敏,黄承龙,黄振光. 基于不同标准老年住院患者潜在不适当用药评价与分析[J]. 中国药物评价,2020,37(6):460-464. DOI:10.3969/j.issn.2095-3593.2020.06.013.
|
[1] | YAO Yuzhong, MA Xiaojun, SONG Huan, ZHONG Yu. The Management Effect of Diabetes "1358 model" on Community Diabetes Patients Based on "Precision Management Combining General Care and Specialty Care" [J]. Chinese General Practice, 2023, 26(34): 4308-4314. |
[2] | QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289. |
[3] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[4] | HUANG Jinling, ZENG Zhirong. The Logic and Trend of Urban Community Health Service Policies in China [J]. Chinese General Practice, 2023, 26(34): 4239-4245. |
[5] | YANG Hui, HU Ruwei, LIU Ruqing, LU Junfeng, WU Jinglan. Relationship between Community Health Service Experience and Glycemic Control Outcomes in Patients with Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(34): 4290-4295. |
[6] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[7] | XU Jian, DAI Fangfang, PAN Wenlei, HUANG Qian, LU Ping, WANG Jianfeng, JIA Huan, YANG Yuqi, HUANG Jiaoling. Visual Analysis of Hotspots and Cutting-edge Trends of Community TCM Service Research in China in the Context of Healthy China [J]. Chinese General Practice, 2023, 26(34): 4343-4350. |
[8] | HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268. |
[9] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[10] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[11] | YIN Zhaoxia, MAO Lidong, ZHANG Baoshuang, HUANG Yin, FENG Yang, WANG Yunfei. Spectrum of Outpatient Illnesses in Children Contracting Family Doctor Services in Shenzhen's Community Settings and Related Implications for Standardized Residency Training of General Practitioners [J]. Chinese General Practice, 2023, 26(33): 4218-4224. |
[12] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[13] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
[14] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[15] | GAO Dekang, WEI Shaohua, MA Xiaoming, DU Peng, XING Chungen, CAO Chun. Risk Factors for Loss of Skeletal Muscle Mass and Its Correlation with Complications after Major Hepatectomy for Liver Cancer [J]. Chinese General Practice, 2023, 26(32): 4031-4037. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||